{"disease":{"id":"brca-mutations","name":"brca mutations"},"drugs":{"marketed":[{"drug_id":"talazoparib-with-enzalutamide","indication_name":"Metastatic castration-resistant prostate cancer (mCRPC) with BRCA1, BRCA2, or ATM gene mutations","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Talazoparib with enzalutamide","generic_name":"talazoparib-with-enzalutamide","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PARP enzymes and androgen receptor","drug_class":"PARP inhibitor and androgen receptor inhibitor","quality_score":10,"revenue":"2194","mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07039552","title":"Development and Validation of an Ovarian Cancer Risk Prediction Model for Family Members of Ovarian Cancer Probands","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Peking University Third Hospital","has_results":false},{"nct_id":"NCT04431024","title":"Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome","phase":"","overall_status":"RECRUITING","enrollment_count":800,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04038905","title":"The Use of Digital Genetic Counselor (DGC) for BRCA1/2 Mutation Carrier Testing","phase":"","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"Igentify Ltd","has_results":false},{"nct_id":"NCT03286842","title":"To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":256,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT02184195","title":"Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":154,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT04038502","title":"Carboplatin or Olaparib for BRcA Deficient Prostate Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"VA Office of Research and Development","has_results":false},{"nct_id":"NCT05960773","title":"Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma","phase":"PHASE2","overall_status":"SUSPENDED","enrollment_count":9,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06654050","title":"Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03123211","title":"Expanded Access to Veliparib","phase":"","overall_status":"NO_LONGER_AVAILABLE","enrollment_count":null,"lead_sponsor_name":"AbbVie","has_results":false}],"total":9},"guidelines":[],"source":"Drug Landscape verified database"}